John Oyler, BeiGene CEO (Endpoints News, PharmCube)
July 14, 2022 07:03 AM EDTUpdated 07:16 AM
China
Pharma
FDA+

No­var­tis’ $650M cash bet on a near-term FDA OK for BeiGene’s Chi­na PD-1? It just got de­layed in­def­i­nite­ly

Amber Tong

A not-so-fun­ny thing hap­pened to No­var­tis’ high-pro­file bid to take a PD-1 check­point out of Chi­na and get it ap­proved in the US this year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times